Related Experiment Video
Updated: Jul 8, 2025
07:08
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
824
Case Report: A complete pathologic response in pancreatic cancer with squamous cell differentiation
Christopher R Grant1, Zhaohui L Arter2, Tran Truc3
1Department of Medicine, University of California Irvine Medical Center, Orange, CA, United States.
Frontiers in Oncology
|December 14, 2023
Summary
Squamous cell carcinoma of the pancreas is rare. A patient achieved a complete pathologic response with chemotherapy, showing a promising treatment outcome for this uncommon pancreatic cancer.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Pancreatic cancer is predominantly adenocarcinoma, with squamous cell carcinoma (SCC) representing a rare subtype (0.5%-1%).
- Limited treatment guidelines and poorly defined options exist for pancreatic SCC due to its rarity.
Observation:
- A 65-year-old male presented with pancreatic carcinoma exhibiting dominant squamous cell differentiation.
- The patient received six cycles of gemcitabine, cisplatin, and nab-paclitaxel chemotherapy every 14 days.
Findings:
- The patient achieved a complete pathologic response (CPR) to the neoadjuvant chemotherapy regimen.
- This represents the first reported case of CPR in pancreatic SCC.
- The patient maintained a high quality of life 7 months post-treatment.
Implications:
- This case suggests a potential effective chemotherapy regimen for pancreatic SCC.
- Highlights the need for further research into treatment strategies for rare pancreatic cancers.
- Emphasizes the possibility of favorable outcomes even in uncommon histological subtypes.
Keywords:
case reportchemotherapycomplete pathologic responsepancreatic cancersquamous cell carcinoma
